Literature DB >> 20590567

Physical and functional interaction between CB1 cannabinoid receptors and beta2-adrenoceptors.

Brian D Hudson1, Terence E Hébert, Melanie E M Kelly.   

Abstract

BACKGROUND AND
PURPOSE: The CB(1) cannabinoid receptor and the beta(2)-adrenoceptor are G protein-coupled receptors (GPCRs) co-expressed in many tissues. The present study examined physical and functional interactions between these receptors in a heterologous expression system and in primary human ocular cells. EXPERIMENTAL APPROACH: Physical interactions between CB(1) receptors and beta(2)-adrenoceptors were assessed using bioluminescence resonance energy transfer (BRET). Functional interactions between these receptors were evaluated by examining receptor trafficking, as well as extracellular signal-regulated kinase (ERK) and cyclic AMP response element binding protein (CREB) signalling. KEY
RESULTS: Physical interactions between CB(1) receptors and beta(2)-adrenoceptors were demonstrated using BRET. In human embryonic kidney (HEK) 293H cells, co-expression of beta(2)-adrenoceptors tempered the constitutive activity and increased cell surface expression of CB(1) receptors. Co-expression altered the signalling properties of CB(1 )receptors, resulting in increased Galpha(i)-dependent ERK phosphorylation, but decreased non-Galpha(i)-mediated CREB phosphorylation. The CB(1) receptor inverse agonist AM251 (N-(piperidin-1-yl)-5-(4-iodophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide) attenuated beta(2)-adrenoceptor-pERK signalling in cells expressing both receptors, while the CB(1) receptor neutral antagonist O-2050 ((6aR,10aR)-3-(1-methanesulfonylamino-4-hexyn-6-yl)-6a,7,10,10a-tetrahydro-6,6,9-trimethyl-6H-dibenzo[b,d]pyran) did not. The actions of AM251 and O-2050 were further examined in primary human trabecular meshwork (HTM) cells, which are ocular cells endogenously co-expressing CB(1) receptors and beta(2)-adrenoceptors. In HTM cells, as in HEK 293H cells, AM251 but not O-2050, altered the beta(2)-adrenoceptor-pERK response. CONCLUSION AND IMPLICATIONS: A complex interaction was demonstrated between CB(1) receptors and beta(2)-adrenoceptors in HEK 293H cells. As similar functional interactions were also observed in HTM cells, such interactions may affect the pharmacology of these receptors in tissues where they are endogenously co-expressed.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20590567      PMCID: PMC2931563          DOI: 10.1111/j.1476-5381.2010.00681.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  80 in total

1.  RNA editing induces variation in desensitization and trafficking of 5-hydroxytryptamine 2c receptor isoforms.

Authors:  Sébastien Marion; David M Weiner; Marc G Caron
Journal:  J Biol Chem       Date:  2003-11-05       Impact factor: 5.157

Review 2.  Roles of G-protein-coupled receptor dimerization.

Authors:  Sonia Terrillon; Michel Bouvier
Journal:  EMBO Rep       Date:  2004-01       Impact factor: 8.807

3.  Hetero-oligomerization between beta2- and beta3-adrenergic receptors generates a beta-adrenergic signaling unit with distinct functional properties.

Authors:  Andreas Breit; Monique Lagacé; Michel Bouvier
Journal:  J Biol Chem       Date:  2004-04-27       Impact factor: 5.157

Review 4.  G protein-coupled receptor dimerization: function and ligand pharmacology.

Authors:  Graeme Milligan
Journal:  Mol Pharmacol       Date:  2004-07       Impact factor: 4.436

5.  Striatal adenosine A2A and cannabinoid CB1 receptors form functional heteromeric complexes that mediate the motor effects of cannabinoids.

Authors:  Paulina Carriba; Oskar Ortiz; Kshitij Patkar; Zuzana Justinova; Jessica Stroik; Andrea Themann; Christa Müller; Anima S Woods; Bruce T Hope; Francisco Ciruela; Vicent Casadó; Enric I Canela; Carme Lluis; Steven R Goldberg; Rosario Moratalla; Rafael Franco; Sergi Ferré
Journal:  Neuropsychopharmacology       Date:  2007-03-14       Impact factor: 7.853

6.  D2 dopamine receptors modulate Galpha-subunit coupling of the CB1 cannabinoid receptor.

Authors:  A Jarrahian; V J Watts; E L Barker
Journal:  J Pharmacol Exp Ther       Date:  2003-11-21       Impact factor: 4.030

7.  Aberrant cannabinoid signaling impairs oviductal transport of embryos.

Authors:  Haibin Wang; Yong Guo; Dingzhi Wang; Philip J Kingsley; Lawrence J Marnett; Sanjoy K Das; Raymond N DuBois; Sudhansu K Dey
Journal:  Nat Med       Date:  2004-09-19       Impact factor: 53.440

Review 8.  The inflow and outflow of anti-glaucoma drugs.

Authors:  David F Woodward; Daniel W Gil
Journal:  Trends Pharmacol Sci       Date:  2004-05       Impact factor: 14.819

Review 9.  CB1 receptors: emerging evidence for central and peripheral mechanisms that regulate energy balance, metabolism, and cardiovascular health.

Authors:  Daniela Cota
Journal:  Diabetes Metab Res Rev       Date:  2007-10       Impact factor: 4.876

10.  Constitutive endocytic cycle of the CB1 cannabinoid receptor.

Authors:  Christophe Leterrier; Damien Bonnard; Damien Carrel; Jean Rossier; Zsolt Lenkei
Journal:  J Biol Chem       Date:  2004-06-21       Impact factor: 5.157

View more
  30 in total

Review 1.  Cannabinoid modulation of noradrenergic circuits: implications for psychiatric disorders.

Authors:  Ana Franky Carvalho; Elisabeth J Van Bockstaele
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2012-01-24       Impact factor: 5.067

2.  Cannabinoid receptor activation correlates with the proapoptotic action of the β2-adrenergic agonist (R,R')-4-methoxy-1-naphthylfenoterol in HepG2 hepatocarcinoma cells.

Authors:  Rajib K Paul; Anuradha Ramamoorthy; Jade Scheers; Robert P Wersto; Lawrence Toll; Lucita Jimenez; Michel Bernier; Irving W Wainer
Journal:  J Pharmacol Exp Ther       Date:  2012-07-09       Impact factor: 4.030

3.  A single dose of cannabidiol reduces blood pressure in healthy volunteers in a randomized crossover study.

Authors:  Khalid A Jadoon; Garry D Tan; Saoirse E O'Sullivan
Journal:  JCI Insight       Date:  2017-06-15

4.  Heteromultimerization of cannabinoid CB(1) receptor and orexin OX(1) receptor generates a unique complex in which both protomers are regulated by orexin A.

Authors:  Richard J Ward; John D Pediani; Graeme Milligan
Journal:  J Biol Chem       Date:  2011-09-09       Impact factor: 5.157

5.  Downregulation of cannabinoid receptor 1 from neuropeptide Y interneurons in the basal ganglia of patients with Huntington's disease and mouse models.

Authors:  Eric A Horne; Jonathan Coy; Katie Swinney; Susan Fung; Allison E T Cherry; William R Marrs; Alipi V Naydenov; Yi Hsing Lin; Xiaocui Sun; C Dirk Keene; Eric Grouzmann; Paul Muchowski; Gillian P Bates; Ken Mackie; Nephi Stella
Journal:  Eur J Neurosci       Date:  2012-11-21       Impact factor: 3.386

Review 6.  Disease-specific heteromerization of G-protein-coupled receptors that target drugs of abuse.

Authors:  Ivone Gomes; Wakako Fujita; Moraje V Chandrakala; Lakshmi A Devi
Journal:  Prog Mol Biol Transl Sci       Date:  2013       Impact factor: 3.622

7.  β-Adrenergic receptor gene expression in HIV-associated neurocognitive impairment and encephalitis: implications for MOR-1K subcellular localization.

Authors:  Seth M Dever; Myosotys Rodriguez; Nazira El-Hage
Journal:  J Neurovirol       Date:  2016-07-11       Impact factor: 2.643

8.  O-2050 facilitates noradrenaline release and increases the CB1 receptor inverse agonistic effect of rimonabant in the guinea pig hippocampus.

Authors:  Bernd Jergas; Kirsten Schulte; Laura Bindila; Beat Lutz; Eberhard Schlicker
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2014-05-23       Impact factor: 3.000

9.  Cortical adrenoceptor expression, function and adaptation under conditions of cannabinoid receptor deletion.

Authors:  B A S Reyes; A F Carvalho; P Szot; D J Kalamarides; Q Wang; L G Kirby; E J Van Bockstaele
Journal:  Exp Neurol       Date:  2017-03-21       Impact factor: 5.330

10.  Cannabinoids as anticancer therapeutic agents.

Authors:  Olga Kovalchuk; Igor Kovalchuk
Journal:  Cell Cycle       Date:  2020-04-05       Impact factor: 4.534

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.